OncoMatch/Clinical Trials/NCT07159204
Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Is NCT07159204 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Paclitaxel polymer micelle immunocombination for biliary tract cancer (btc).
Treatment: Paclitaxel polymer micelle immunocombination — After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Cholangiocarcinoma
Disease stage
Required: Stage IIIA, IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — first-line
Patients were intolerant or failed for ≥1 month after first-line systemic therapy
Cannot have received: immune checkpoint inhibitor
previously received treatment with immune checkpoint inhibitors
Cannot have received: VEGFR inhibitor (lenvatinib)
previously received treatment with ... lenvatinib
Cannot have received: taxane (paclitaxel)
previously received treatment with ... paclitaxel
Cannot have received: systemic anti-tumor treatment
Exception: treatment allowed if completed ≥4 weeks before randomization
Any systemic anti-tumor treatment received within the three months prior to participating in the study ... Treatment is allowed 4 weeks before randomization.
Lab requirements
Blood counts
adequate, based on laboratory results within 14 days prior to initiation of investigational therapy
Kidney function
creatinine ≤1.5×ULN, or creatinine clearance >50mL/min; renal insufficiency: creatinine ratio >3.5g/24 hours, urine protein ≥++, or 24-hour urine protein quantification >1.0g, or renal failure requiring dialysis excluded
Liver function
liver function within CTCAE grade 1 elevation; bilirubin >3×ULN excluded; jaundice, ascites excluded
Hematology and organ function are adequate ... Adequate renal function: creatinine ≤1.5×ULN, or creatinine clearance >50mL/min ... Liver insufficiency: Characterized by jaundice, ascites and/or bilirubin >3×ULN [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07159204 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, VEGFR inhibitor, taxane disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIA or IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages